The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor

Neuroscience Letters

Volumn 544, Issue , 2013, Pages 68-73

  Xue, Rui ^a   Zhang, Yan Ping ^a   Jin, Zeng Liang ^a   Yuan, Li ^a   He, Xin Hua ^a   Zhao, Nan ^a   Chen, Hong Xia ^a   Zhang, Li Ming ^a   Fan, Shi Yong ^a   Zhong, Bo Hua ^a   Zhang, You Zhi ^a   Li, Yun Feng ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Antidepressants; Behavioral despair models; Dual reuptake inhibitors; Integrated evaluation system; Monoamine transporters

Indexed keywords

07091 9A; 070919 A; 071017 S; 071026 W; 071031 B; 080307 A; 080307 B; DULOXETINE; NORADRENALIN; RADIOLIGAND; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG BINDING; DRUG DETERMINATION; DRUG EFFICACY; DRUG SCREENING; FORCED SWIMMING TEST; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; LD 50; LOCOMOTION; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MICE; MICE, INBRED ICR; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS; SURVIVAL RATE;

EID: 84878422095     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.076     Document Type: Article

References (25)

1. Bliss C.I. Statistics in Biology 1967, New York, McGraw-Hill Book Company.
2. Bymaster F.P., Lee T.C., Knadler M.P., Detke M.J., Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des. 2005, 11:1475-1493.
3. Deecher D.C., Beyer C.E., Johnston G., Bray J., Shah S., Abou-Gharbia M., Andree T.H. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther. 2006, 318:657-665.
4. Eli Lilly and Company Eli Lilly and Company Annual Report: Eli Lilly and Company, 2012 2011, http://investor.lilly.com/financials.cfm.
5. Favis W.A. The history of Marsilid. J. Clin. Exp. Psychopathol. 1958, 19:1-10.
6. Iranikhah M., Wensel T.M., Thomason A.R. Vilazodone for the treatment of major depressive disorder. Pharmacotherapy 2012, 32:958-965.
7. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: agomelatine a new antidepressant with an innovative mechanism of action. World J. Biol. Psychiatry 2009, 10:117-126.
8. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
9. Kuhn R. Über die Behandlung depressiver Zustände mit einem Iminodibenzylderivat (G22355). Schweiz. Med. Wochenschr. 1957, 87:1135-1140.
10. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003, 28:402-412.
11. O'Neil M.F., Moore N.A. Animal models of depression: are there any?. Hum. Psychopharmacol. 2003, 18:239-254.
12. Pacher P., Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr. Pharm. Des. 2004, 10:2463-2475.
13. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
14. Prange A.J., Wilson I.C., Lynn C.W., Alltop L.B., Stikeleather R.A. l-Tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch. Gen. Psychiatry 1974, 30:56-62.
15. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychophamacology (Berl) 1998, 138:1-8.
16. Rénéric J.P., Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998, 136:190-197.
17. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122:509-522.
18. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
19. Suzuki M., Kumazawa N., Ohta S., Kamogawa A., Shinoda M. Protective effects of antioxidants on experimental liver injuries. Yakugaku Zasshi. 1990, 110:697-701.
20. Wong D.T., Perry K.W., Bymaster F.P. The discovery of fluoxetine hydrochloride (PROZAC). Nat. Rev. Drug Discov. 2005, 4:764-774.
21. Xue R., Jin Z.L., Chen H.X., Yuan L., He X.H., Zhang Y.P., Meng Y.G., Xu J.P., Zheng J.Q., Zhong B.H., Li Y.F., Zhang Y.Z. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. Eur. Neuropsychopharmacol. 2012, 10.1016/j.euroneuro.2012.06.001.
22. Xue R., Xu X.D., Li N.M., Zhang Y.Z., Li Y.F. Pharmacodynamic and toxicological evaluation of duloxetine. Chin. Pharmacol. Bull. 2011, 27:1471-1475.
23. Xue R., Zhang Y.Z., Zou L.B. Progress in the development of early-onset antidepressants. Chin. Pharmacol. Bull. 2008, 24:1558-1560.
24. Xue R., Zhang Y.Z., Li Y.F. System for antidepressant evaluation of monoamine reuptake inhibitors. Chin. Pharmacol. Bull. 2011, 27:1636-1640.
25. Zhang Y.Z., Li Y.F., Yu N.J., Yuan L., Zhao Y.M., Xiao W.B., Luo Z.P. Antidepressant-like effects of the ethanolic extract of Xiaobuxin-Tang, a traditional Chinese herbal prescription in animal models of depression. Chin. Med. J. 2007, 120:1792-1796.